From 2024 to 2031, the CAGR of the worldwide High-Throughput Screening (HTS) market is expected to be 7.2%. From USD 16.9 billion in 2022 to USD 30.1 billion by 2031 the market value is predicted to rise. Over the projection period, North America is expected to control the market.
The rising need for drug discovery and development techniques is driving notable expansion in the High-throughput Screening (HTS) industry. HTS technologies provide effective and reasonably priced alternatives for screening vast chemical libraries as pharmaceutical and biotechnology businesses try to speed their research processes. Adoption of automation, miniaturization, and sophisticated data processing methods has greatly improved the capabilities of HTS platforms, therefore becoming them vital instruments in current drug development activities.
Market Trend: Growing acceptance in HTS processes of artificial intelligence and machine learning
By means of the incorporation of artificial intelligence and machine learning techniques, HTS data analysis and interpretation is transforming and quicker and more accurate identification of potential drug candidates is made possible. These technologies improve predictive modeling, lower false positives, and maximize screening techniques, therefore hastening the drug development process. AI-powered HTS systems can examine intricate biological data, spot trends, and provide insights maybe not clear-cut using more conventional approaches. More complex HTS systems and fresh prospects for software and analytics firms in the health sciences industry are resulting from this trend driving growth. Integration of artificial intelligence and machine learning into HTS processes is predicted to become more common as their capabilities develop, hence enhancing the efficiency and success rates of drug development projects.
Market Drivers: Increasing need for tailored treatments and individualized medications
High-throughput screening methods are in demand as personalised medicine and targeted therapeutics receive more and more importance. Pharmacists are concentrating on creating medications that target certain biochemical pathways and genetic profiles as healthcare moves toward more customized treatment techniques. Through fast screening of vast chemical libraries against particular disease targets or patient-derived cell lines, HTS is very vital in this procedure. This method lets scientists find possible medication options more likely to be successful for certain patient groups or disease subtypes. The capacity of HTS to concurrently screen many drugs and produce enormous volumes of data fits very well with the demands of individualized medicine research. Furthermore improving its value in finding new targets and biomarkers for focused treatments is the inclusion of genomes and proteomics data into HTS processes. Demand for increasingly advanced and specialized HTS technologies is predicted to rise as the area of customized medicine develops, therefore stimulating innovation and market growth.
Market Restraints: High startup expenditures and running expenses connected with HTS technologies
High-throughput screening platforms need for large upfront equipment, automated system, and specific consumable investments. For smaller research teams or academic institutions, the cost of procuring and maintaining modern HTS apparatus like robotic liquid handling systems, plate readers, and imaging devices might be prohibitively high. The whole financial load also includes reagents, assay development, and data management infrastructure—all of which are continuing running expenses. The intricacy of HTS systems often requires professional workers for operation and maintenance, therefore adding to the labor expenses. Particularly in developing countries or among smaller biotech companies with limited resources, these high prices might restrict the use of HTS technology. Some companies may be forced by budgetary restrictions to outsource their screening requirements to contract research organizations (CROs) instead of building in-house capability. Manufacturers of equipment are working on scalable, reasonably priced HTS solutions to meet this difficulty. For many potential users, nonetheless, the large initial outlay continues to be a major obstacle to entrance, thereby maybe holding down market development in certain sectors or areas.
Dominating the Technology section are cell-based assays.
Rising as the top technology in the High-Throughput Screening industry, cell-based assays provide unmatched understanding of drug effects on live cells. In early-stage drug development, these tests provide more physiologically relevant data than biochemical assays, therefore facilitating improved prediction of therapeutic effectiveness and toxicity. Screening drugs in complicated cellular settings enables researchers to concurrently examine target engagement, pathway regulation, and possible off-target effects, therefore addressing many criteria. Emphasizing phenotypic screening and identification of new targets, this all-encompassing strategy fits extremely well with the present trends in drug development. Cell-based assays' adaptability along with developments in cell culture methods and reporter systems have helped them to be widely used in the biotechnology and pharmaceutical sectors. Cell-based assays are predicted to keep their prominent place in the HTS technology scene as the need for more predictive and translational screening models keeps rising.
North America leads High-Throughput Screening Market
Driven by strong pharmaceutical and biotechnology industries as well as large R&D expenditures, North America leads the world in High-Throughput Screening market. The area's market supremacy is a result of its great concentration of established research facilities, big pharmaceutical businesses, and favorable legal environment. With a great concentration of HTS facilities and experience, the United States in particular stands out as a major center for drug discovery and development operations. Early adoption of cutting-edge technology by the area, including automated systems and AI-driven screening platforms, has strengthened its market-position. Leading HTS equipment manufacturers and service providers also provide simple access to modern technologies and support services for end customers in North America. The area's emphasis on precision medicine projects and the rising trend of academic-industry cooperation in drug development could help to maintain its supremacy in the HTS market throughout the projected period. North America is probably going to stay at the forefront of HTS technology adoption and innovation as pharmaceutical corporations keep spending in creative screening techniques to solve challenging ailments and speed up drug development schedules.
Strong rivalry among both existing companies and new technology suppliers defines the High-Throughput Screening market. Important players in the industry include specialist biotechnology businesses, big pharmaceutical corporations with internal HTS capacity, and equipment makers. To keep their competitive advantage, top players are emphasizing technical developments, strategic alliances, and broadening of their product ranges. Larger organizations purchasing smaller, creative businesses to improve their screening capacity and increase their service offerings has helped the industry to show a trend toward consolidation. Filling the outsourcing demands of pharmaceutical and biotechnology firms, contract research organizations (CROs) specialized in HTS services are likewise becoming more and more important. Companies are funding the development of AI-powered platforms, smaller assay formats, and new detection technologies as the need for increasingly complex and integrated screening solutions rises. Regional businesses rising in Asia-Pacific markets that provide reasonably priced screening solutions and services shapes the competitive scene even more.
- Thermo Fisher Scientific Inc.
- Agilent Technologies, Inc.
- Danaher Corporation
- PerkinElmer, Inc.
- Tecan Group Ltd.
- Merck KGaA
- Bio-Rad Laboratories, Inc.
- Beckman Coulter, Inc. (Danaher Corporation)
- Hamilton Company
- Aurora Biomed Inc.
1. INTRODUCTION
1.1. Market Definition
1.2. Study Scope
1.3. Currency Conversion
1.4. Study Period (2022- 2031)
1.5. Regional Coverage
2. RESEARCH METHODOLOGY
2.1. Primary Research
2.2. Secondary Research
2.3. Company Share Analysis
2.4. Data Triangulation
3. EXECUTIVE SUMMARY
3.1. Global High-Throughput Screening (HTS) Market (2018 – 2022)
3.2. Global High-Throughput Screening (HTS) Market (2023 – 2031)
3.2.1. Market Segment By Technology (2023 – 2031)
3.2.2. Market Segment By Application (2023 – 2031)
3.2.3. Market Segment By End User (2023 – 2031)
4. MARKET DYNAMICS
4.1. Market Trends
4.1.1. Increasing adoption of artificial intelligence and machine learning in HTS workflows
4.1.2. Growing focus on phenotypic screening approaches
4.1.3. Rising demand for miniaturized assay formats
4.2. Market Drivers
4.2.1. Rising demand for personalized medicine and targeted therapies
4.2.2. Increasing R&D investments in pharmaceutical and biotechnology sectors
4.2.3. Advancements in automation and robotics technologies
4.3. Market Restraints
4.3.1. High initial investment and operational costs associated with HTS technologies
4.3.2. Complexity in data management and analysis
4.4. Porter's Five Forces Analysis
4.4.1. Threat of New Entrants
4.4.2. Bargaining Power of Buyers/Consumers
4.4.3. Bargaining Power of Suppliers
4.4.4. Threat of Substitute Products
4.4.5. Intensity of Competitive Rivalry
4.5. Supply Chain Analysis
4.6. Pricing Analysis
4.7. Regulatory Analysis
4.8. Pipeline Analysis
5. BY TECHNOLOGY (MARKET VALUE (US$ MILLION) – 2022-2031*)
5.1. Cell-Based Assays
5.2. Lab-on-a-Chip
5.3. Ultra-High-Throughput Screening
5.4. Bioinformatics
5.5. Label-Free Technology
6. BY APPLICATION
6.1. Drug Discovery
6.2. Biochemical Screening
6.3. Life Sciences Research
6.4. Toxicology
6.5. Others
7. BY END USER
7.1. Pharmaceutical Companies
7.2. Biotechnology Companies
7.3. Academic & Research Institutes
7.4. Contract Research Organizations (CROs)
7.5. Others
8. REGION
8.1. North America
8.1.1. United States
8.1.2. Canada
8.1.3. Mexico
8.2. South America
8.2.1. Brazil
8.2.2. Argentina
8.2.3. Rest of South America
8.3. Europe
8.3.1. Germany
8.3.2. United Kingdom
8.3.3. France
8.3.4. Italy
8.3.5. Spain
8.3.6. Russia
8.3.7. Rest of Europe
8.4. Asia-Pacific
8.4.1. China
8.4.2. Japan
8.4.3. India
8.4.4. Australia
8.4.5. South Korea
8.4.6. Rest of Asia-Pacific
8.5. Middle-East
8.5.1. UAE
8.5.2. Saudi Arabia
8.5.3. Turkey
8.5.4. Rest of Middle East
8.6. Africa
8.6.1. South Africa
8.6.2. Egypt
8.6.3. Rest of Africa
9. COMPETITIVE LANDSCAPE
9.1. Key Developments
9.2. Company Market Share Analysis
9.3. Product Benchmarking
10. SWOT ANALYSIS
11. COMPANY PROFILES
11.1. Thermo Fisher Scientific Inc.
11.2. Agilent Technologies, Inc.
11.3. Danaher Corporation
11.4. PerkinElmer, Inc.
11.5. Tecan Group Ltd.
11.6. Merck KGaA
11.7. Bio-Rad Laboratories, Inc.
11.8. Beckman Coulter, Inc. (Danaher Corporation)
11.9. Hamilton Company
11.10. Aurora Biomed Inc.
11.11. Molecular Devices, LLC
11.12. BMG LABTECH GmbH (*LIST NOT EXHAUSTIVE)
12. MARKET OPPORTUNITIES
By Technology:
By Application:
By End User:
By Region:
We at Aurorawave Intellects Market Report gives total market analysis that suit our customer business need and permit decision maker to run organizations without any problem. We have accomplished greatness in giving start to finish market research arrangements. Our detachment of industry specialists accumulate key data and get ready substance that lines up with our customer's business/specialty.
We at aurorawaveintellects.com offer mainly 3 types of licenses:
• Single User: Research Report copy can be distributed to a single user only
• Multi User: Research Report distribution is restricted up to 5 users.
• Corporate License :Research Report can be distributed across the company.
Based on the nature of the topic or research, the formats vary. The different formats of the report are as following:
• Word Document
• PPT
Following modes are available for making the payment:
• Online Payment (Visa Card, Master Card, Stripe)
• Razorpay
• Net Banking
• Bank Wire Transfer
Our customer service and research specialist team are available by phone and by email. Customer service hours are 24X7 Indian Standard Time (IST). You may reach us at:
• Email: info@aurorawaveintellects.com
• United Kingdom: ++91 7382742511
